Plans are solidifying for a unique solution to both commercial and emergent relief manufacturing of SkinTE™ and future Polarity products. As we prepare for market entry in 2018, our established relationship with CTRM creates a springboard for the anticipated scale-up to address the large burn and chronic wound markets, with the pursuit of our own independent manufacturing facility. In addition, CTRM manufactures a variety of regenerative medicine products, is FACT accredited, and has technical expertise in current Good Tissue Practice (cGTP) and current Good Manufacturing Practice (cGMP).ĭenver Lough, MD, PhD, Chairman and CEO, stated, 'This agreement with CTRM should provide PolarityTE™ with rapid clinical translation of the promising products we are developing, and takes us one step closer to achieving our goal of clinical application of our launch product, SkinTE™. CTRM is the established manufacturer of hematopoietic stem cell transplants for renowned institutions of the Salt Lake region such as the Huntsman Cancer Institute and Primary Children's Hospital. ('Polarity') (NASDAQ: COOL) announces the signing of a manufacturing agreement with Cell Therapy and Regenerative Medicine ('CTRM') at the University of Utah School of Medicine.

SALT LAKE CITY, UT - (Marketwired) - 04/20/17.

Polarity te